Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics Inc.||4||0.00||N/A||-0.81||0.00|
|Zynerba Pharmaceuticals Inc.||10||2943.80||N/A||-2.27||0.00|
Table 1 highlights Brainstorm Cell Therapeutics Inc. and Zynerba Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 provides the net margins, return on equity and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics Inc.||0.00%||-236.6%||-115.3%|
|Zynerba Pharmaceuticals Inc.||0.00%||-64.1%||-54.9%|
Risk and Volatility
Brainstorm Cell Therapeutics Inc. has a 1.19 beta, while its volatility is 19.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Zynerba Pharmaceuticals Inc.’s beta is 4.82 which is 382.00% more volatile than Standard & Poor’s 500.
The Current Ratio and Quick Ratio of Brainstorm Cell Therapeutics Inc. are 1 and 1 respectively. Its competitor Zynerba Pharmaceuticals Inc.’s Current Ratio is 9.9 and its Quick Ratio is 9.9. Zynerba Pharmaceuticals Inc. can pay off short and long-term obligations better than Brainstorm Cell Therapeutics Inc.
In next table is delivered Brainstorm Cell Therapeutics Inc. and Zynerba Pharmaceuticals Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics Inc.||0||0||1||3.00|
|Zynerba Pharmaceuticals Inc.||0||0||1||3.00|
Brainstorm Cell Therapeutics Inc.’s upside potential is 121.67% at a $9 consensus price target. Competitively the consensus price target of Zynerba Pharmaceuticals Inc. is $18, which is potential 47.30% upside. The information presented earlier suggests that Brainstorm Cell Therapeutics Inc. looks more robust than Zynerba Pharmaceuticals Inc. as far as analyst belief.
Insider and Institutional Ownership
Brainstorm Cell Therapeutics Inc. and Zynerba Pharmaceuticals Inc. has shares owned by institutional investors as follows: 11.4% and 24.8%. Brainstorm Cell Therapeutics Inc.’s share owned by insiders are 0.6%. Comparatively, 13.78% are Zynerba Pharmaceuticals Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Brainstorm Cell Therapeutics Inc.||0.75%||-0.25%||2.82%||8.97%||-2.43%||12.96%|
|Zynerba Pharmaceuticals Inc.||-7.75%||-24.95%||-11.08%||110.54%||56.43%||256.57%|
For the past year Brainstorm Cell Therapeutics Inc.’s stock price has smaller growth than Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc. on 6 of the 8 factors.
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.
Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.